Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.
| Revenue (Most Recent Fiscal Year) | $266.27M |
| Net Income (Most Recent Fiscal Year) | $-50.42M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.43 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -22.05% |
| Net Margin (Trailing 12 Months) | -22.31% |
| Return on Equity (Trailing 12 Months) | -759.04% |
| Return on Assets (Trailing 12 Months) | -24.63% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 5.74 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.09 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.98 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 64.68M |
| Free Float | 60.74M |
| Market Capitalization | $397.17M |
| Average Volume (Last 20 Days) | 1.11M |
| Beta (Past 60 Months) | 1.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.69% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |